Bristol Myers Squibb earnings calendar draws closer, shares on NASDAQ in focus

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-26, 14:08.

Bristol Myers Squibb (US0897961004) enters the next earnings cycle with several late-stage pipeline and regulatory milestones that will feed directly into its coming quarterly reports. The stock continues to trade on the New York Stock Exchange, with investors watching how guidance and drug launch data shape consensus expectations according to recent analyst commentary. A recent Reuters market report on large U.S. pharma guidance and launches highlights ongoing scrutiny of Bristol Myers Squibb alongside peers such as Merck and Pfizer.

What the next earnings may show

Bristol Myers Squibb typically reports quarterly results and provides updates on its key oncology and immunology franchises, including Opdivo and Eliquis, in late July or early August based on its historical earnings cadence. In recent months the company has updated investors on revenue trends, cost measures and the uptake of new products such as the cancer therapy Abecma across U.S. and European markets, which will be reflected in the next set of results according to its investor presentations. The Bristol Myers Squibb quarterly-results section sets out the past reporting dates and offers detailed financial data that analysts use to refine their models.

Market participants on Wall Street follow the upcoming earnings closely, as the stock forms part of the S&P 500 health care cohort alongside Johnson & Johnson and AbbVie. Recent sector pieces from major financial media note that large-cap pharma names with solid balance sheets and dividends are under review for their ability to offset patent expiries with new product launches, a theme that also applies to Bristol Myers Squibb. This scheduled earnings update therefore represents an important checkpoint for assessing how its mix of mature brands and newer therapies supports revenue and margin stability, as described in recent coverage of the U.S. pharmaceuticals sector.

Analyst expectations for the stock

Sell-side analysts largely maintain neutral to constructive views on Bristol Myers Squibb stock, but they point to execution risks around patent cliffs and competition in immuno-oncology. Recent consensus summaries on financial-data platforms indicate that a majority of covering analysts rate the shares at Hold or Buy, with a wide range of 12-month price targets that reflect differing assumptions about peak sales for pipeline assets. These targets offer a benchmark but are subject to change once the company publishes fresh quarterly numbers and updates its outlook.

Commentary from major houses such as Goldman Sachs and JPMorgan has emphasized that free cash flow generation and disciplined capital allocation, including share repurchases and bolt-on acquisitions, are key components of the investment case for Bristol Myers Squibb. Analysts also watch any revisions to earnings-per-share guidance and R&D spending plans, which can shift sentiment quickly in the days after an earnings release. According to recent analyst notes on U.S. large-cap pharma, stocks that deliver even modest beats to expectations and confirm medium-term guidance often see a more supportive share-price reaction compared with those that merely meet forecasts.

The product behind the stock

Bristol Myers Squibb generates a substantial share of its revenue from the cancer immunotherapy Opdivo, which targets PD-1 to help the immune system recognize and attack tumor cells. The drug is approved across several indications, including lung, kidney and melanoma cancers, and continues to be a strategic pillar in the company’s oncology portfolio alongside other treatments. Management regularly highlights Opdivo’s performance and label-expansion efforts in its investor materials, underscoring its role in the broader transformation of Bristol Myers Squibb’s product mix toward innovative therapies.

The listing in brief

As of 2026-06-26, 14:00, Bristol Myers Squibb shares last traded at approximately 42.50 USD on the New York Stock Exchange.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.